JPRN-UMIN000044136
Completed
未知
Retrospective study of trifluridine/tipiracil hydrochloride plus bevacizumab for vulnerable patients with previously treated metastatic colorectal cancer(WJOG14520G) - Retrospective study of trifluridine/tipiracil hydrochloride plus bevacizumab for vulnerable patients with previously treated metastatic colorectal cancer(WJOG14520G)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- West Japan Oncology Group
- Enrollment
- 140
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of chemotherapy including regorafenib, FTD/TPI, or investigational drug prior to FTD/TPI plus BEV
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapyER-positive breast cancerMetastatic breast cancerHer2 negative10006291NL-OMON52884BOOG Study Center50
Active, not recruiting
Phase 2
TAS102 in patients with ER-positive, HER2-negative advanced breast cancer (TIBET study)2024-519204-27-00BOOG Study Center B.V.50
Not yet recruiting
Not Applicable
A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancerJPRN-UMIN000051378The 22nd Century Cutting-Edge Medical Informaion Technology Organization15
Active, not recruiting
Phase 1
Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a secondline therapy in patients with bile duct cancerPatients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002936-26-DEHeinrich-Heine-University Düsseldorf28
Active, not recruiting
Phase 1
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroesophageal cancerCTIS2023-508724-35-00nicancer73